<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03338777</url>
  </required_header>
  <id_info>
    <org_study_id>2082</org_study_id>
    <nct_id>NCT03338777</nct_id>
  </id_info>
  <brief_title>Suicide Plus Immune Gene Therapy for Advanced Melanoma</brief_title>
  <acronym>IGTM-101</acronym>
  <official_title>Phase 1 Suicide Plus Immune Gene Therapy for Advanced Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Italiano de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Oncología Ángel H. Roffo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Agencia Nacional de Promoción Científica y Tecnológica, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Council of Scientific and Technical Research, Argentina</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Facultad de Medicina. Universidad de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Italiano de Buenos Aires</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety evaluation of combined immunogene therapy in patients with advanced melanoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This phase I clinical protocol is proposed to evaluate the safety of combined immunotherapy
      genetics in humans.

      This treatment combines the high local cytotoxicity of the suicide gene system (HSV thymidine
      kinase: HSVt k) / prodrug (ganciclovir: GCV) with the immunostimulation of interleukin2
      (hIL2) and immunoamplification of granulocyte and macrophage colony stimulating factor
      (hGMCSF) in the presence of tumor antigens.

      The proposed scheme consists in the periodic intra / peritumoral application of plasmid DNA
      complexes: cationic lipid (lipoplexes) containing the HSVtk gene, co-administered with the
      prodrug GCV, and subcutaneous injections of a vaccine (LGvax) produced with formolized
      extracts of allogeneic melanoma combined with lipoplexes carrying the hIL2 and hGMCSF genes.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 13, 2017</start_date>
  <completion_date type="Anticipated">September 13, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Suicide plus immunogene therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety reported as the number of treatment-related adverse events as assessed by CTCAE v4.03</measure>
    <time_frame>1 year</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 (https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf).</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>Suicide plus immunogene therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra and peritumoral infiltrates with multiple injections of lipoplexes carrying the HSVtk suicide gene co-administered with GCV and subcutaneous vaccine produced with formolized allogeneic tumor extracts and lipoplexes carrying hIL-2 and hGM-CSF genes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Suicide plus immunogene therapy</intervention_name>
    <description>Intra and peritumoral infiltrates with multiple injections of 0.1 ml/cm2 or 0.2 ml/cm3 of lipoplexes bearing the HSVtk suicide gene (1: 1; 1 mg/ml, according to tumor size), co-administered with GCV (12.5 mg/ml). Patients start with a minimum of 0.5 ml and at the 3rd week, the maximum dose is scaled according to the tumor size up to 2 ml maximum.
Treated simultaneously with a subcutaneous vaccine produced with:
Formolized allogeneic tumor extracts and,
Lipoplexes carrying hIL-2 and hGM-CSF genes (0.5 mg each).</description>
    <arm_group_label>Suicide plus immunogene therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically and / or cytologically confirmed melanoma.

          -  Patients progressed or are intolerant to conventional systemic treatments.

          -  Patients that are not candidates for surgery under oncologic criteria (complete
             resection).

          -  Performance status (ECOG) 0 or 1.

          -  Patients with life expectancy greater than 6 months.

          -  Patients with at least one accessible target lesion for gene inoculation (superficial
             localizations of the primary tumor, satelitosis, subcutaneous or accessible lymph node
             metastasis).

          -  Patients with measurable disease (according to RECIST 1.1 criteria, irrespective of
             the target lesion chosen for suicide gene inoculation)

          -  Patients with signed informed consent.

        Exclusion Criteria:

          -  Patients with uncontrolled cardiovascular disease

          -  Patients with uncontrolled respiratory disease.

          -  Patients with uncontrolled immune disease.

          -  Patients with glucocorticoids or immunosuppressive drugs or agents with
             immunomodulatory activity (except non-steroidal anti-inflammatory agents) up to 2
             weeks before treatment.

          -  Patients performing other experimental therapies.

          -  Patients who are pregnant or breastfeeding.

          -  Patients undergoing concurrent chemotherapy or radiation therapy.

          -  Uncontrolled diabetes.

          -  Patients with active diagnosis of other malignant neoplasms.

          -  HIV-positive patients.

          -  Uncontrolled thyroid abnormality.

          -  Patients with significant medical morbidity.

          -  Patients with a history of allergic reactions to chemicals or similar to those used in
             this study.

          -  Metastasis in the central nervous system.

          -  Laboratory eligibility criteria excluded:

               -  Hemoglobin: &lt;8 g / dL, leukocytes: &lt;3,000 / mm3, platelets: &lt;100,000 / mm3,
                  neutrophils: &lt;1000 / mm3, hematocrit: &lt;25%. bilirubin&gt; 2.0 mg / dL, GOT or GPT:
                  2.5 times&gt; than normal upper institutional limit (ULN), alkaline phosphatase: 2
                  times&gt; ULN, creatinine&gt; 2.0 mg / dL, creatinine clearence : &lt;60 ml / min / 1.73
                  m2.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ventura Simonovich, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Italiano</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ventura Simonovich, MD</last_name>
    <phone>49590866</phone>
    <phone_ext>4153</phone_ext>
    <email>ventura.simonovich@hospitalitaliano.org.ar</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Heliana Hernández, MD</last_name>
    <email>heliana.hernandez@hospitalitaliano.org.ar</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Italiano</name>
      <address>
        <city>Ciudad Autónoma de Buenos Aires</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guadalupe Pallotta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heliana de Lourdes Hernández Herrera, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2017</study_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Italiano de Buenos Aires</investigator_affiliation>
    <investigator_full_name>Simonovich Ventura, MD</investigator_full_name>
    <investigator_title>Medical Doctor</investigator_title>
  </responsible_party>
  <keyword>melanoma</keyword>
  <keyword>lipoplexes</keyword>
  <keyword>plasmid</keyword>
  <keyword>herpes simplex thymidine kinase</keyword>
  <keyword>interleukin-2</keyword>
  <keyword>granulocyte-macrophage colony-stimulating factor</keyword>
  <keyword>tumor vaccine</keyword>
  <keyword>suicide gene</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Suicide</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

